ARTICLE | Company News
Neos rises after ADHD approval
January 29, 2016 2:29 AM UTC
Neos Therapeutics Inc. (NASDAQ:NEOS) gained $3.96 (42%) to $13.38 on Thursday after FDA approved Adzenys XR-ODT ( NT-0202) to treat ADHD in patients aged six and older. Chief Commercial Officer Thomas McDonnell said Neos expects to launch the drug in mid-2Q16, and has not yet determined a price.
The company said FDA approved Adzenys XR-ODT via the 505(b)(2) pathway after Neos demonstrated its bioequivalence to approved ADHD drug Adderall XR dextroamphetamine/amphetamine from Shire plc (LSE:SHP; NASDAQ:SHPG). ...